Tango Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 23, 2026, 6:36 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedTango Therapeutics (TNGX) Reports 82% ORR in 2L/3L Pancreatic Cancer With Vopimetostat plus Daraxonrasib, Plans Phase 3 for 1H 2027 and Cuts Workforce 14%
8-KAug. 11, 2026, 5:13 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 11, 2026, 7:20 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KAug. 6, 2026, 5:30 p.m. ETView on SEC.gov
Departure/appointment of directors or officers